27 January 2016

Consortium members presence at congresses

Members from the Pediatric Praziquantel Consortium have continued to showcase program progresses and to foster interactions with experts and stakeholders through active participation at international conferences across the world.


Daniel Lacerda de Oliveira sharing the latest results
of the pediatric praziquantel program

14th International Symposium on Schistosomiasis

In August, at the ‘14th International Symposium on Schistosomiasis’ held in Brazil, Consortium partners Merck KGaA (Darmstadt, Germany) and Farmanguinhos, Fiocruz (Brazil) presented the program confirming the commitment to make a suitable medication available to very young children in the coming years. “The urgent need for a pediatric praziquantel formulation was clearly highlighted at the conference. “The Brazilian scientific community acknowledged the efforts of the Consortium to develop an orodispersible tablet formulation for young children” said Daniel Lacerda de Oliveira, “We, at Farmanguinhos, are extremely proud of our contribution to the program and to be part of the Consortium”.

 


9th European Congress on Tropical Medicine and International Health. (ECTMIH)

At the ‘9th European Congress on Tropical Medicine and International Health. (ECTMIH)’ 6-10 September Basel (Switzerland), the significant presence of the Consortium members and the exhibition booth allowed the Consortium to benefit from the wide networking platform offered by the ECTMIH congress for dialogues and exchanges.

Consortium team explaining the pediatric praziquantel development program

 

 

 

 

 

 

 

 

 

 

 

This congress, organized by Consortium partner the Swiss Tropical and Public Health Institute and counting of around 2000 participants from 102 countries, was the most highly attended one since its creation 20 years ago. The two scientific presentations from the Consortium shared publicly, for the first time, the results from the Phase I bioavailability trials as well as of the taste study, raising a high level of interest from the scientific community on the program.

Wilma Bagchus (Merck KGaA) and Eric Huber (Swiss TPH) presenting the outcome of the
Phase I L-PZQ ODT trial and the taste study, respectively. 

 

 

 

 

 

 

 

 

 

 

 

The Consortium thanks DNDi and the GHIT Fund for the kind invitation to join their symposia. The simultaneous presence of Merck with two satellite symposia on ‘co-infections’ and on the Global Schistosomiasis Alliance as well as an exhibition stand showed the participants the width and synergies arising from a multiple approach in the fight against schistosomiasis. “Five days of intense engagement with representatives from the scientific community, many from Africa”, said Consortium coordinator Remco de Vrueh (Lygature), “reconfirmed to me and the rest of the team the importance and need for a novel pediatric praziquantel formulation”.


64th American Society of Tropical Medicine and Hygiene’ (ASTMH)

At the world wide renown ‘64th American Society of Tropical Medicine and Hygiene’ (ASTMH) congress in Philadelphia (US), Jutta Reinhard-Rupp from Merck KGaA (Darmstadt, Germany) presented how the Pediatric PZQ consortium program, with its new project of developing a new drug for pre-school children is part of a whole integrated approach to fight schistosomiasis globally. The poster presentation animated fruitful discussions with the participants who encouraged to pursue our effort of developing the new formulation to be ready as soon as possible.


30th Japan Association for International Health Congress

In November 2015, Consortium partner Astellas Pharma Inc. organized a luncheon meeting at the 30th Japan Association for International Health Congress held in Kanazawa (Japan) and Astellas colleagues Yu Hasegawa and Atsushi Sakurai presented progresses of the program with focus on the formulation activities and on the results from the taste study. Participants confirmed high expectations for an early availability of the new pediatric formulation and showed a significant interest on formulation developments for its contribution to Global Health.


Symposium for International Research and Innovation in Schistosomiasis (SIRIS)

The Consortium will continue to be very active at a number of conferences and events in 2016, starting with the Symposium for International Research and Innovation in Schistosomiasis (SIRIS) early February. Consortium partner, Merck KGaA (Darmstadt, Germany) is amongst the co-organizers of this scientific conference and plans to showcase the efforts and the progress of the Pediatric Praziquantel program during the event, also in the context of scientific discussions on female genital schistosomiasis (FGS).